Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.6
5.0
Journals
Polymers
Special Issues
Polymers for Biomedical Imaging and Therapy II
share announcement

Polymers for Biomedical Imaging and Therapy II

A special issue of Polymers (ISSN 2073-4360). This special issue belongs to the section "Biomacromolecules, Biobased and Biodegradable Polymers".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2668

Special Issue Editor

Dr. Mohamed F. Attia

E-Mail Website
Guest Editor
Department of Chemistry, Clemson University, Clemson, SC 29634, USA
Interests: designation of nano/micro polymer particles for diagnosis and/or treatment of various kinds of diseases, notably cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in polymer science are critical to the successful development of multi-component composites in particulate systems for biomedical applications. They hold great promise due to their facile synthesis and excellent biocompatibility, tolerability, and bioavailability. Polymer material platforms, including polymer–drug conjugates, polymeric micelles, polymersomes, and dendrimers, are extensively used in theranostic nanomedicine, enabling the molecular diagnosis, targeted drug delivery, and the simultaneous monitoring and treatment of diseases. 

This Special Issue is a collection of original research papers, reviews, and communications that addresses the synthesis and formulation of polymer particles containing imaging agents (iodine, gold, SPIONPs, gadolinium, etc.), therapeutics (DNA, siRNA, proteins, small drugs, etc.), and targeting moieties to develop an efficient delivery system. These multifunctional polymeric particles will help overcome challenges in clinical nanomedicine and could provide good therapeutic outcomes to patients.

Dr. Mohamed F. Attia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Polymers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • polymer
  • nano and micro-particles
  • drug delivery
  • imaging
  • therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 2910 KiB  
Article
Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies
by Mohamed M. Badran, Abdulrahman E. Alanazi, Mohamed Abbas Ibrahim, Doaa Hasan Alshora, Ehab Taha and Abdullah H. Alomrani
Polymers 2023, 15(19), 3890; https://doi.org/10.3390/polym15193890 - 26 Sep 2023
Cited by 4 | Viewed by 1008
Abstract
Bromocriptine mesylate (BM), primarily ergocryptine, is a dopamine agonist derived from ergot alkaloids. This study aimed to formulate chitosan (CS)-coated poly ε-caprolactone nanoparticles (PCL NPs) loaded with BM for direct targeting to the brain via the nasal route. PCL NPs were optimized using [...] Read more.
Bromocriptine mesylate (BM), primarily ergocryptine, is a dopamine agonist derived from ergot alkaloids. This study aimed to formulate chitosan (CS)-coated poly ε-caprolactone nanoparticles (PCL NPs) loaded with BM for direct targeting to the brain via the nasal route. PCL NPs were optimized using response surface methodology and a Box–Behnken factorial design. Independent formulation parameters for nanoparticle attributes, including PCL payload (A), D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) concentration (B), and sonication time (C), were investigated. The dependent variables were nanoparticle size (Y1), zeta potential (Y2), entrapment efficiency (EE; Y3), and drug release rate (Y4). The optimal formulation for BM-PCL NPs was determined to be 50 mg PCL load, 0.0865% TPGS concentration, and 8 min sonication time, resulting in nanoparticles with a size of 296 ± 2.9 nm having a zeta potential of −16.2 ± 3.8 mV, an EE of 90.7 ± 1.9%, and a zero-order release rate of 2.6 ± 1.3%/min. The optimized BM-PCL NPs were then coated with CS at varying concentrations (0.25, 0.5, and 1%) to enhance their effect. The CS-PCL NPs exhibited different particle sizes and zeta potentials depending on the CS concentration used. The highest EE (88%) and drug load (DL; 5.5%) were observed for the optimized BM-CS-PCL NPs coated with 0.25% CS. The BM-CS-PCL NPs displayed a biphasic release pattern, with an initial rapid drug release lasting for 2 h, followed by a sustained release for up to 48 h. The 0.25% CS-coated BM-CS-PCL NPs showed a high level of permeation across the goat nasal mucosa, with reasonable mucoadhesive strength. These findings suggested that the optimized 0.25% CS-coated BM-CS-PCL NPs hold promise for successful nasal delivery, thereby improving the therapeutic efficacy of BM. Full article
(This article belongs to the Special Issue Polymers for Biomedical Imaging and Therapy II)
►▼ Show Figures

Figure 1

14 pages, 1897 KiB  
Article
Fabrication and Assessment of Orodispersible Tablets Loaded with Cubosomes for the Improved Anticancer Activity of Simvastatin against the MDA-MB-231 Breast Cancer Cell Line
by Randa Mohammed Zaki, Amal El Sayeh Abou El Ela, Alanood S. Almurshedi, Basmah Nasser Aldosari, Abdullah A. Aldossari and Mohamed A. Ibrahim
Polymers 2023, 15(7), 1774; https://doi.org/10.3390/polym15071774 - 02 Apr 2023
Cited by 3 | Viewed by 1366
Abstract
Various factors limit the use of simvastatin as an anticancer drug. Therefore, this study aimed to analyse simvastatin (SIM)-loaded cubosome efficacy against breast cancer. SIM-loaded cubosomes were prepared using the emulsification method using different glyceryl monooleate, Pluronic F127 (PF-127), and polyvinyl alcohol (PVA) [...] Read more.
Various factors limit the use of simvastatin as an anticancer drug. Therefore, this study aimed to analyse simvastatin (SIM)-loaded cubosome efficacy against breast cancer. SIM-loaded cubosomes were prepared using the emulsification method using different glyceryl monooleate, Pluronic F127 (PF-127), and polyvinyl alcohol (PVA) ratios. The best cubosomal formula was subjected to an in vitro cytotoxicity analysis using the human breast cancer cell line, MDA-MB-231 (MDA) (ATCC, HTB-26), and formulated as oral disintegrating tablets through direct compression. PF-127 and PVA positively affected drug loading, and the entrapment efficiency percentage of different SIM-cubosomal formulations ranged from 33.52% to 80.80%. Vesicle size ranged from 181.9 ± 0.50 to 316.6 ± 1.25 nm. PF-127 enhanced in vitro SIM release from cubosome formulations due to its solubilising action on SIM. The in vitro dissolution analysis indicated that SIM exhibited an initial dissolution of 10.4 ± 0.25% within the first 5 min, and 63.5 ± 0.29% of the loaded drug was released after 1 h. Moreover, cubosome formula F3 at 25 and 50 µg/mL doses significantly decreased MDA cell viability compared to the 12.5 µg/mL dose. The untreated SIM suspension and drug-free cubosomes at all doses had no significant influence on MDA cell viability compared to the control. Full article
(This article belongs to the Special Issue Polymers for Biomedical Imaging and Therapy II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop